US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Johnson & Johnson

JNJNYSE

168.23

USD
-0.66
(-0.39%)
Market Closed
25.00P/E
15Forward P/E
1.26P/E to S&P500
439.834BMarket CAP
2.63%Div Yield

Johnson & Johnson

NYSE:JNJ

RECENT
PRICE

168.23

P/E
RATIO

25.00

(PEG:0.60)

P/E RATIO
RELATIVE
TO S&P

1.26

DIV
YLD

2.54%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

0.57 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 01/23:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2010

2011

2012

2012

2013

2014

2016

2017

2017

2018

2019

2021

2022

TTM

Fiscal year

18.14

3.76

3.92

1.45

21.20

3.67

4.14

1.62

22.67

4.61

4.23

1.79

22.43

4.44

5.15

1.93

22.49

4.87

5.11

2.12

23.87

3.55

4.19

2.26

24.19

3.91

4.49

2.38

25.28

4.90

4.90

2.58

26.71

5.86

5.30

2.79

25.43

5.59

5.74

2.97

26.56

6.11

5.74

3.19

28.50

0.48

6.63

3.33

30.64

5.75

6.96

3.57

31.17

5.74

7.57

3.77

31.37

5.59

7.67

3.98

35.63

7.93

7.51

4.19

36.57

7.28

6.75

4.39

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.93

13.38

1.15

15.03

1.09

15.12

0.86

18.33

0.87

20.66

1.06

20.95

1.06

23.33

1.27

26.25

1.33

25.06

1.26

25.82

1.19

26.02

1.22

22.43

1.38

22.44

1.33

22.59

1.27

24.04

1.39

28.12

1.46

28.53

CAPEX per share

Book Value per share

2,940

2,882

2,812

2,760

2,738

2,724

2,778

2,821

2,783

2,755

2,707

2,683

2,662

2,633

2,633

2,632

2,626

Comm.Shares outs.(m)

- -

- -

- -

17.4

1.0

2.5%

14.0

0.7

2.8%

13.9

0.7

3.1%

13.0

0.8

3.3%

18.9

1.3

3.4%

17.2

1.2

3.6%

17.4

1.0

3.0%

17.1

0.9

2.8%

20.3

0.9

2.6%

21.2

0.9

2.5%

267.4

11.3

2.6%

23.1

0.9

2.7%

23.5

1.0

2.8%

29.6

1.0

2.4%

21.6

1.0

2.4%

25.0

1.3

2.5%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (2/10/22 | Q3)

Total liabilities
$100,525 m.

Total assets
$175,124 m.

Long-term debt
$27,603 m.

Cash and equiv.
$11,355 m.

Goodwill $33,383 m.

Retained earnings $127,917 m.

Common stock 2,617 m. shares

Market Capitalisation
$439,834 m. (as of 29/1/23)

65,030

24.8%

67,224

25.3%

71,312

26.6%

74,331

28.4%

70,074

26.1%

71,890

29.4%

76,450

25.0%

81,581

26.0%

82,059

25.6%

82,584

24.1%

93,775

26.2%

96,041

24.9%

Revenue (m)

Operating margin

3,158

9,672

3,666

10,853

4,104

13,831

3,895

16,323

3,746

15,409

3,754

16,540

5,642

1,300

6,929

15,297

7,009

15,119

7,231

14,714

7,390

20,878

7,041

19,157

Depreciation (m)

Net profit (m)

21.8%

14.9%

23.7%

16.1%

10.6%

19.4%

20.6%

22.0%

19.7%

22.0%

16.5%

23.0%

92.6%

1.7%

15.0%

18.8%

12.7%

18.4%

10.8%

17.8%

8.3%

22.3%

13.8%

20.0%

Income tax rate

Net profit margin

31,505

12,969

57,080

21,854

11,489

64,826

30,732

13,328

74,053

34,226

15,122

69,752

32,463

12,857

71,150

38,745

22,442

70,418

12,551

30,675

60,160

14,803

27,684

59,752

9,310

26,494

59,471

8,744

32,635

63,278

15,753

29,985

74,023

19,693

27,603

74,599

Working capital (m)

Long-term debt (m)

Equity (m)

11.1%

11.4%

16.9%

11.5%

12.1%

16.7%

13.3%

12.0%

18.7%

15.8%

16.1%

23.4%

15.0%

14.8%

21.7%

14.9%

14.5%

23.5%

1.1%

11.8%

2.2%

13.3%

12.4%

25.6%

12.6%

11.2%

25.4%

11.2%

9.5%

23.3%

15.4%

12.6%

28.2%

15.0%

12.9%

25.7%

ROIC

Return on capital

Return on equity

Working Capital

2019

2021

2022

Cash assets

19,287

27,771

28,273

Receivables

14,481

13,576

15,283

Inventory

9,020

9,344

10,387

Other

2,486

3,132

3,701

Current assets

45,274

51,237

60,979

Acc. Payable

8,544

9,505

11,055

Debt due

1,202

2,631

3,766

Other

26,218

30,357

30,405

Current liab.

35,964

42,493

45,226

36.4%

76.1%

39.1%

156.7%

47.3%

78.3%

52.4%

100.9%

47.0%

85.1%

47.9%

113.2%

(587.9)%

86.1%

37.9%

82.9%

34.4%

83.7%

28.8%

67.9%

47.2%

73.3%

39.9%

97.1%

Plowback ratio

Div.&Repurch. to FCF

Johnson & Johnson (US) started trading on September 1, 1944 (cik: 0000200406), operates in the Healthcare sector (Drug Manufacturers—General industry), has 141,700 full-time employees, and is led by Mr. Alex Gorsky. Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

5.37%

3.89%

Cash flow

2.74%

5.38%

Earnings

278.69%

118.87%

Dividends

5.39%

5.86%

Book value

5.56%

1.90%

Insider trading

Type

Shares

Date

Duato Joaquin

Exempt

148,538

01/17/23

Duato Joaquin

InKind

98,795

01/17/23

Duato Joaquin

Exempt

148,538

01/17/23

Gorsky Alex

Exempt

547,692

01/17/23

Gorsky Alex

InKind

366,610

01/17/23

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2021

20,691

18,336

21,082

22,475

82,584

2022

22,321

23,312

23,338

24,804

93,775

2023

23,426

24,020

23,791

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2021

2.20

1.38

1.35

0.66

5.59

2022

2.35

2.39

1.39

1.80

7.93

2023

1.96

1.83

1.70

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2021

0.95

1.01

1.01

1.01

3.98

2022

1.01

1.06

1.06

1.06

4.19

2023

1.06

1.13

1.13

- -

- -

01/24/2023

J&J Gets Ready to Break Up With Tylenol

The Wall Street Journal - Read more...

01/24/2023

Johnson & Johnson Profit Falls 25%

The Wall Street Journal - Read more...

01/13/2023

J&J Slashes Production of Its Covid-19 Vaccine

The Wall Street Journal - Read more...

11/02/2022

J&J Makes a $16.6 Billion Bet on Heart Pumps to Lift Medical-Device Sales

The Wall Street Journal - Read more...

11/01/2022

J&J Agrees to Buy Heart-Device Maker Abiomed for $16.6 Billion

The Wall Street Journal - Read more...

10/18/2022

Johnson & Johnson Isn’t Rushing Into M&A

The Wall Street Journal - Read more...

09/28/2022

Band-Aid and Tylenol Company to Be Named Kenvue

The Wall Street Journal - Read more...

09/16/2022

Jurist Noted for Bankruptcy Expertise Will Weigh J&J Talc Appeal

The Wall Street Journal - Read more...

07/19/2022

Johnson & Johnson Trims Full-Year Guidance on Stronger Dollar

The Wall Street Journal - Read more...

06/06/2022

J&J Plans to End Covid-19 Vaccine Deal With Emergent BioSolutions

The Wall Street Journal - Read more...

05/24/2022

Covid-19 Vaccine and Drug Sales, Once Booming, Plateau

The Wall Street Journal - Read more...

05/11/2022

J&J Names Executives of Tylenol, Band-Aid Company

The Wall Street Journal - Read more...

05/05/2022

FDA Limits Use of Johnson & Johnson’s Covid-19 Vaccine

The Wall Street Journal - Read more...

05/04/2022

J&J Sues Drug-Benefit Middleman Over Drug-Cost Assistance Program

The Wall Street Journal - Read more...

04/26/2022

Johnson & Johnson Sues Alleged HIV-Drug Counterfeiters

The Wall Street Journal - Read more...

04/19/2022

Johnson & Johnson Backs Off Covid Vaccine Sales Guidance

The Wall Street Journal - Read more...

04/18/2022

J&J Settles With West Virginia in Opioid Suit for $99 Million

The Wall Street Journal - Read more...

03/30/2022

Justice Department Probes Alleged Sales of Counterfeit HIV Drugs

The Wall Street Journal - Read more...

02/28/2022

FDA Approves Cell-Based Therapy for Blood Cancer Discovered in China

The Wall Street Journal - Read more...

02/25/2022

Johnson & Johnson, Drug Distributors Agree to Opioid Settlement With States

The Wall Street Journal - Read more...

02/25/2022

Judge Backs J&J’s Talc Bankruptcy, Keeping Cancer Lawsuits Frozen

The Wall Street Journal - Read more...

02/02/2022

Native American Tribes Reach $590 Million Opioid Settlement

The Wall Street Journal - Read more...

01/25/2022

Johnson & Johnson Posts Higher Quarterly Sales Despite Some Pandemic-Related Pains

The Wall Street Journal - Read more...

01/25/2022

AMC, IBM, Microsoft, GE: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

12/17/2021

Rivian, FedEx, Cerner, Oracle: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

12/17/2021

CDC Recommends Pfizer, Moderna Covid-19 Vaccines Over J&J’s

The Wall Street Journal - Read more...

12/06/2021

J&J Prepares to Untangle Finances Ahead of Planned Split

The Wall Street Journal - Read more...

11/29/2021

Omicron Variant Has Covid-19 Vaccine Makers Preparing for Worst Case

The Wall Street Journal - Read more...

11/29/2021

Moderna, Coinbase, Occidental, Royal Caribbean: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/26/2021

J&J Covid-19 Vaccine Recipients Shift to Other Boosters

The Wall Street Journal - Read more...

11/21/2021

Most Vulnerable More at Risk of Breakthrough Hospitalization

The Wall Street Journal - Read more...

11/12/2021

What to Know About Johnson & Johnson’s Breakup

The Wall Street Journal - Read more...

11/12/2021

Johnson & Johnson Breakup Is No Clean Sweep

The Wall Street Journal - Read more...

11/12/2021

Johnson & Johnson to Split Consumer From Pharmaceutical, Medical-Device Businesses, Creating Two Companies

The Wall Street Journal - Read more...

11/12/2021

Rivian Automotive Stock Price: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/12/2021

J&J Split Sees Band-Aid, Tylenol Go Their Own Way

The Wall Street Journal - Read more...

11/12/2021

How Bankruptcy Could Help Johnson & Johnson Corral Vast Talc Litigation

The Wall Street Journal - Read more...

11/11/2021

J&J Talc Bankruptcy Case Moved to New Jersey From North Carolina

The Wall Street Journal - Read more...

11/09/2021

Johnson & Johnson Opioid Verdict Overturned by Oklahoma Supreme Court

The Wall Street Journal - Read more...

11/03/2021

Vaccine Boosters’ Mix-and-Match Efficacy

The Wall Street Journal - Read more...

11/02/2021

Opioid Manufacturers Score Win in California Lawsuit

The Wall Street Journal - Read more...

10/22/2021

Moderna and J&J Covid-19 Booster Shots Backed by CDC

The Wall Street Journal - Read more...

10/20/2021

FDA Authorizes Covid-19 Vaccine Boosters From Moderna, J&J

The Wall Street Journal - Read more...

10/19/2021

Johnson & Johnson’s Sales Climb Across Divisions

The Wall Street Journal - Read more...

10/19/2021

Johnson & Johnson’s Stock Deserves a Booster

The Wall Street Journal - Read more...

10/19/2021

Dover, Procter & Gamble, Travelers, Netflix: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

10/18/2021

FDA Nears Approval for Mixing Covid-19 Booster Shots

The Wall Street Journal - Read more...

10/18/2021

Zillow, State Street, Valneva, Upstart: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

10/15/2021

J&J Covid-19 Booster Shot Endorsed by FDA Advisers

The Wall Street Journal - Read more...

10/13/2021

J&J Booster Dose Bolsters Protection Against Covid-19, FDA Says

The Wall Street Journal - Read more...

10/12/2021

Johnson & Johnson’s Top Scientist to Depart

The Wall Street Journal - Read more...

10/05/2021

Johnson & Johnson Asks FDA to Authorize Covid-19 Booster

The Wall Street Journal - Read more...

09/17/2021

Moderna’s Covid-19 Shot Best Prevents Hospitalization, Study Indicates

The Wall Street Journal - Read more...

09/04/2021

Covid-19 Vaccine Booster Launch Could Be Delayed for Many

The Wall Street Journal - Read more...

08/31/2021

Zoom Video, AMC, CrowdStrike: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

08/28/2021

Covid-19 Vaccine Efficacy: What Do the Numbers Really Mean?

The Wall Street Journal - Read more...

08/25/2021

J&J Says Covid-19 Booster Prompts Strong Immune Response

The Wall Street Journal - Read more...

08/17/2021

As Delta Surges, Covid-19 Breakthrough Cases Remain Uncommon

The Wall Street Journal - Read more...

08/12/2021

Vaccine Scammers Target Authorities in Dozens of Countries

The Wall Street Journal - Read more...

08/12/2021

FDA Moving Toward Decision Authorizing Booster Shot for Immunocompromised

The Wall Street Journal - Read more...

08/06/2021

J&J Vaccine Highly Effective Against Delta Variant in South African Trial

The Wall Street Journal - Read more...

08/03/2021

U.S. Has Shared 110 Million Covid-19 Vaccine Doses Overseas

The Wall Street Journal - Read more...

07/29/2021

J&J Contractor Plans to Resume Covid-19 Vaccine Production at Troubled Plant

The Wall Street Journal - Read more...

07/21/2021

Johnson & Johnson Posts Higher Quarterly Profit

The Wall Street Journal - Read more...

07/21/2021

Coca-Cola, Johnson & Johnson, Chipotle: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

07/20/2021

$26 Billion Opioid Settlement Expected This Week

The Wall Street Journal - Read more...

07/15/2021

Blackstone, AIG, NortonLifeLock, Morgan Stanley: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

07/12/2021

FDA Warns J&J Covid-19 Vaccine Raises Risk of Rare Neurological Condition

The Wall Street Journal - Read more...

07/02/2021

J&J Vaccine Shows Promise Protecting Against Delta Variant

The Wall Street Journal - Read more...

06/26/2021

Johnson & Johnson Settles New York Opioid Case for $230 Million

The Wall Street Journal - Read more...

06/16/2021

Roblox, Oracle, Greenland Tech, Kindred Biosciences: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

06/11/2021

FDA Approves Export of Covid-19 Vaccine Doses From Troubled Plant

The Wall Street Journal - Read more...

06/08/2021

Millions of J&J Covid-19 Vaccines Are at Risk of Expiring in June

The Wall Street Journal - Read more...

06/01/2021

Supreme Court Won’t Consider Johnson & Johnson Challenge to Baby Powder Judgment

The Wall Street Journal - Read more...

05/28/2021

FDA, J&J Near Deal for Vaccine Production at Baltimore Plant

The Wall Street Journal - Read more...

05/09/2021

J&J Vaccine Pause Stoked Hesitancy That Threatens Covid-19 Vaccination Drive

The Wall Street Journal - Read more...

05/07/2021

AstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emergency-Use Application

The Wall Street Journal - Read more...

05/06/2021

U.S. Backs Waiver of Intellectual Property Protection for Covid-19 Vaccines

The Wall Street Journal - Read more...

05/02/2021

Opioid-Crisis Lawsuit Heads for Trial in West Virginia

The Wall Street Journal - Read more...